Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2014

01-11-2014 | Research Article

Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in patients with B-cell non-Hodgkin lymphomas using BIOMED-2 protocol

Authors: S. Ghorbian, I. Jahanzad, G. R. Javadi, E. Sakhinia

Published in: Clinical and Translational Oncology | Issue 11/2014

Login to get access

Abstract

Purpose

Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in formalin-fixed, paraffin-embedded (FFPE) tissue of patients with B-cell non-Hodgkin lymphomas (B-NHL).

Materials and methods

This study was performed on samples from 70 patients with B-NHL, including two cases of follicular lymphoma (FL), 20 cases of diffuse large B-cell lymphoma (DLBCL), one case of mantle cell lymphoma (MCL), and 47 cases of B-cell neoplasm (non-classified), which had been previously assessed for complete IGH clonality, and failure to clarify gene rearrangements. We used a gold standard multiplex PCR protocol provided by European Biomedicine and Health (BIOMED-2) Concerted Action Project BMH4-CT98-3936 for improvement of diagnosis and analysis of clonality gene rearrangement in lymphoma malignancies.

Results

Our results revealed a total positive monoclonality of 89 % (62/70) in Igκ, Igλ, and 11.4 % (8/70) polyclonality in gene rearrangements assay. The samples with positive clonality consisting (Igκ: 45 %, Igλ: 55 %) in DLBCL, (Igκ: 100 %) in FL, (Igλ: 100 %) in MCL, and (Igκ: 47 %, Igλ: 36 %) in B-cell neoplasm non-classified. None of the incomplete IGH D–J immunoglobulin gene families (0 %) showed monoclonality, and all samples demonstrated polyclonality pattern.

Conclusions

Our findings on FFPE tissue revealed that immunoglobulin light chains clonality gene rearrangements assays using BIOMED-2 protocol, could be considered a valuable and reliable method for clonality detection, particularly in cases of failure of complete IGH gene rearrangements analysis. Clonal Ig gene rearrangements assay is applicable for routine diagnostic testing of lymphoproliferative disorders and as a reliable method for differentiating between malignant and benign lymphoma disorders.
Literature
1.
World Health Organization. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.
2.
Schuetz JM, Daley D, Leach S, Conde L, Berry BR, Gallagher RP, et al. Non-Hodgkin lymphoma risk and variants in genes controlling lymphocyte development. PLoS ONE. 2013;8:e75170.PubMedCrossRefPubMedCentral
3.
Visser OJ, Perk LR, Zijlstra JM, van Dongen GA, Huijgens PC, van de Loosdrecht AA. Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease. BioDrugs. 2006;20:201–7.PubMedCrossRef
4.
Alt FW, Oltz EM, Young F, Gorman J, Taccioli G, Chen J. VDJ recombination. Immunol Today. 1992;13:306–14.PubMedCrossRef
5.
González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110:3112–21.PubMedCrossRef
6.
Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012;120:4407–17.PubMedCrossRefPubMedCentral
7.
Küppers R, Zhao M, Hansmann M, Rajewsky K. Tracing B-cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J. 1993;12:4955.PubMedPubMedCentral
8.
Li A-H, Rosenquist R, Forestier E, Lindh J, Roos G. Detailed clonality analysis of relapsing precursor B acute lymphoblastic leukemia: implications for minimal residual disease detection. Leuk Res. 2001;25:1033–45.PubMedCrossRef
9.
Szczepański T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002;99:2315–23.PubMedCrossRef
10.
He J, Wu J, Jiao Y, Wagner-Johnston N, Ambinder RF, Diaz LA Jr, et al. IgH gene rearrangements as plasma biomarkers in non-Hodgkin’s lymphoma patients. Oncotarget. 2011;2:178.PubMedPubMedCentral
11.
Van Dongen J, Langerak A, Brüggemann M, Evans P, Hummel M, Lavender F, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.PubMedCrossRef
12.
Evans P, Pott C, Groenen P, Salles G, Davi F, Berger F, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2006;21:207–14.PubMedCrossRef
13.
Langerak AW, van Dongen JJ. Multiple clonal Ig/TCR products: implications for interpretation of clonality findings. J Hematopathology. 2012;5:35–43.CrossRef
14.
Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol. 1994;145:1301.PubMedPubMedCentral
15.
Langerak A, Groenen P, Brüggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26:2159–71.PubMedCrossRefPubMedCentral
16.
Shan G-D, Hu F-L, Yang M, Chen H-T, Chen W-G, Wang Y-G, et al. Clonal immunoglobulin heavy chain and T-cell receptor γ gene rearrangements in primary gastric lymphoma. World J Gastroenterol WJG. 2013;19:5727.CrossRef
17.
Van Krieken J, Langerak A, Macintyre E, Kneba M, Hodges E, Sanz RG, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2006;21:201–6.PubMedCrossRef
18.
Shin S, Kim AH, Park J, Kim M, Lim J, Kim Y, et al. Analysis of immunoglobulin and T cell receptor gene rearrangement in the bone marrow of lymphoid neoplasia using BIOMED-2 multiplex polymerase chain reaction. Int J Med Sci. 2013;10:1510.PubMedCrossRefPubMedCentral
19.
Mannu C, Gazzola A, Bacci F, Sabattini E, Sagramoso C, Roncolato F, et al. Use of IGK gene rearrangement analysis for clonality assessment of lymphoid malignancies: a single center experience. Am J Blood Res. 2011;1:167.PubMedPubMedCentral
20.
Kim Y, Choi YD, Choi C, Nam J-H. Diagnostic utility of a clonality test for lymphoproliferative diseases in Koreans using the BIOMED-2 PCR assay. Korean J Pathol. 2013;47:458–65.PubMedCrossRefPubMedCentral
21.
Ly B, Cotta CV. The utility of the BIOMED-2 primers in the detection of 2 clonal, B-Lymphoproliferative disorders simultaneously involving the same site. Arch Pathol Lab Med. 2013;137:1654–9.PubMedCrossRef
22.
Sung J-Y, Kang SY, Kim S-H, Kwon JE, Ko Y-H. Analysis of immunoglobulin gene rearrangement: comparison between BIOMED-2 multiplex PCR and conventional nested PCR. Lab Med Online. 2011;1:195–201.CrossRef
23.
Payne K, Wright P, Grant JW, Huang Y, Hamoudi R, Bacon CM, et al. BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. Br J Haematol. 2011;155:84–92.PubMedCrossRef
24.
Berget E, Helgeland L, Molven A, Vintermyr OK. Detection of clonality in follicular lymphoma using formalin-fixed, paraffin-embedded tissue samples and BIOMED-2 immunoglobulin primers. J Clin Pathol. 2011;64:37–41.PubMedCrossRef
25.
Halldorsdottir AM, Zehnbauer BA, Burack WR. Application of BIOMED-2 clonality assays to formalin-fixed paraffin embedded follicular lymphoma specimens: superior performance of the IGK assays compared to IGH for suboptimal specimens. Leukemia & lymphoma. 2007;48:1338–43.CrossRef
Metadata
Title
Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in patients with B-cell non-Hodgkin lymphomas using BIOMED-2 protocol
Authors
S. Ghorbian
I. Jahanzad
G. R. Javadi
E. Sakhinia
Publication date
01-11-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1188-4

Other articles of this Issue 11/2014

Clinical and Translational Oncology 11/2014 Go to the issue

EDUCATIONAL SERIES – BLUE SERIES

The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets

Educational series – Red Series

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer

Research Article

Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib

Original Article

Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base

Research Article

Stromal expression of carbonic anhydrase IX in esophageal cancer

Brief Research Article

Genetic disorders of pediatric MEN2A patients in the south of Spain
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits